Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Manogue

Clinical Cardiac Electrophysiology Asheville, NC Medical Doctor

NPI 1417183054 CMS profile 4223399

5 Vanderbilt Park Dr, Asheville, NC 28803

Open in the dashboard

General payments

$230,063

560 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$6,648 paid to institutions, not to them · program years 2021–2022

Through program year 2025, Michael Manogue of Asheville, NC is reported in the CMS Open Payments database as having received $230,063 across 560 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $6,648 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $146,510 179
2024 General $39,962 134
2023 General $22,221 85
2022 General $7,541 49
2021 General $3,089 14
2020 General $6,552 39
2019 General $4,187 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Manogue
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Michael Manogue were reported at $146,510. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Michael Manogue Clinical Cardiac Electrophysiology median Middle half National median
2019 $4,187 $2,361 $585–$8,260 $163
2020 $6,552 $993 $247–$4,351 $114
2021 $3,089 $1,185 $326–$4,739 $132
2022 $7,541 $2,073 $554–$6,789 $149
2023 $22,221 $2,568 $759–$8,159 $160
2024 $39,962 $2,557 $703–$7,403 $164
2025 $146,510 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $155,883 177 payments
  2. Medtronic, Inc. $62,679 242 payments
  3. Medtronic Vascular, Inc. $4,880 32 payments
  4. Biosense Webster, Inc. $3,754 21 payments
  5. Abbott Laboratories $695 11 payments
  6. Atricure, Inc. $486 10 payments
  7. Biotronik Inc. $382 5 payments
  8. Actelion Pharmaceuticals US, Inc. $258 15 payments
  9. Vektor Medical Inc. $252 1 payment
  10. Pfizer Inc. $168 8 payments
  11. Other $627 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $168,627 58 payments
  2. Consulting Fee $25,688 13 payments
  3. Food and Beverage $19,947 415 payments
  4. Travel and Lodging $15,681 72 payments
  5. Education $120 2 payments
Products named General payments · program years 2019–2025
  1. General - EP $99,894 33 payments
  2. SelectSecure $7,537 68 payments
  3. Rhythmia Mapping System Rhythmia Simulator_CRM $7,250 3 payments
  4. FARAPULSE Farapulse_Rm $5,968 5 payments
  5. Cable, IntellaNav Ablation Catheter $4,000 1 payment
  6. Arctic Front $3,464 21 payments
  7. FARAPULSE Farapulse_Ep $3,423 8 payments
  8. Carto 3 $3,187 21 payments
  9. General - Therapies $3,000 6 payments
  10. Rhythmia Mapping System Rhythmia_EP $2,161 51 payments
  11. Other $12,255 252 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,399

Median for Internal Medicine: 777

Drug cost

$506,920

Median for Internal Medicine: $73,373

Branded share of claims

35.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 242 $260,945
Xarelto Rivaroxaban Brand 114 $135,741
Entresto Sacubitril/Valsartan Brand 42 $35,548
Multaq Dronedarone Hcl Brand 15 $30,415
Dofetilide Generic 154 $21,977
Jardiance Empagliflozin Brand 14 $10,183
Metoprolol Succinate Generic 157 $3,497
Flecainide Acetate Generic 38 $1,404
Clonidine Generic 12 $927
Amiodarone Hcl Generic 84 $907

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$266,474

Medicare's payments for the services billed

Medicare patients

710

Average age 77

Services billed

4,092

296 women, 414 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 68%
Heart failure 49%
Ischemic heart disease 47%
Arthritis 46%
Chronic kidney disease 35%
Diabetes 33%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $52
  • E.R. Squibb & Sons, L.L.C. $21
$74 242 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $56
$56 14 —
XARELTO
  • Janssen Pharmaceuticals, Inc $42
$42 114 —
PAXLOVID
  • PFIZER INC. $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

560 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record